Search

Displaying results 2351 - 2360 of 10000 in total
  1. Drug

    Samidorphan

    go.drugbank.com/drugs/DB12543
    ApprovedInvestigational

    [A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™ … Samidorphan has been shown in animal models and clinical trials to ameliorate [olanzapine]-induced weight gain and metabolic dysfunction.

  2. Drug

    Temozolomide

    go.drugbank.com/drugs/DB00853
    ApprovedInvestigational

    [L32033] Temozolomide was granted FDA approval on August 11, 1999, as an oral capsule and subsequently on February 27, 2009, as an intravenous injection. … [A229853, A229888, A229923, L32033] Following initial hydrolysis, further reactions liberate a highly reactive methyl diazonium cation capable of methylating various residues on adenosine and guanine bases

    Products: TEMODAL 140MG HKP IN BTL, TEMODAL 180MG HKP IN BTL
  3. Drug

    AMGN-0007

    go.drugbank.com/drugs/DB06511
    Experimental

    Recombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.

  4. Drug

    Quinethazone

    go.drugbank.com/drugs/DB01325
    Approved

    Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.

  5. Drug

    Degarelix

    go.drugbank.com/drugs/DB06699
    ApprovedInvestigational

    FDA approved on December 24, 2008. … Reduction in testosterone is important in treating men with advanced prostate cancer.

  6. Drug

    Methadone

    go.drugbank.com/drugs/DB00333
    ApprovedInvestigational

    [A185876] Compared to other opioids, methadone's effects on NMDA inhibition may explain it's improved analgesic efficacy and reduced opioid tolerance. … [A185888,A185891,A185897] Compared with [morphine], the gold standard reference opioid, methadone also acts as an agonist of κ- and σ-opioid receptors, as an antagonist of the N-methyl-D-aspartate (NMDA

    Categories: Drugs Used in Opioid Dependence, Drugs Used in Addictive Disorders
  7. Drug

    Miglustat

    go.drugbank.com/drugs/DB00419
    ApprovedInvestigational

    Miglustat was first developed as an anti-HIV agent in the 1990s. … It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric patients in the European Union, Brazil, and South Korea.

    Synonyms: N-(n-Butyl)deoxynojirimycin, N-Butylmoranoline
  8. Drug

    Atosiban

    go.drugbank.com/drugs/DB09059
    ApprovedInvestigational

    It was first reported in the literature in 1985. Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women. … Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor.

    Products: Atosiban Accord 6,75 mg/0,9 ml Injektionslösung in einer Fertigspritze
  9. Drug

    Pirbuterol

    go.drugbank.com/drugs/DB01291
    ApprovedWithdrawn

    In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. … in a concentration between 10-50%.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    [L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and

    Synonyms: (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)- 1-methyl-1H-pyrazole-4-carboxamide, (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide